Spero.jpg
Spero Therapeutics Announces $5.9 Million Award from U.S. Department of Defense to Further Clinical Development of SPR206
July 16, 2019 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28, 2019 17:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 28, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis
June 20, 2019 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference
June 17, 2019 08:30 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Announces $10 Million Registered Direct Offering of Common Stock
June 13, 2019 08:00 ET | Spero Therapeutics, Inc.
Novo Holdings A/S through its Novo REPAIR Impact Fund to Invest Up to $10 million Net Proceeds to Advance Spero’s SPR720 CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics,...
Spero.jpg
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2019 17:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review
May 09, 2019 16:10 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2019 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:  SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
April 08, 2019 08:30 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis
March 29, 2019 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...